Preface

As the Editor-in-Chief of “Current Drug Research Reviews” (CDRR, online ISSN: 2589-9783, print ISSN: 2589-9775; formerly Current Drug Abuse Reviews), a peer-reviewed journal, I wish a warm welcome to all the readers to this new volume. CDRR is an international peer-reviewed journal, which publishes research articles, review articles and clinical studies on the design and development of new drugs, including drug targeting, medicinal chemistry, in-silico drug design, combinatorial chemistry, meta-analyses, drug abuse and addiction, drug-drug interactions and enzyme kinetics; species scaling and extrapolations; drug transporters; target organ toxicity and inter-individual variability in drug exposure-response; extrahepatic metabolism; bio-activation, reactive metabolites, high-throughput screening, drug targets and structure-activity relationships. There is no restriction on the length of a paper.

Currently, CDRR is indexed in Cabells Journalytics, Chemical Abstracts Service/SciFinder, ChemWeb, CNKI Scholar, Dimensions, EBSCO, EMBASE, EMCare, Genamics JournalSeek, Google Scholar, J-Gate, JournalTOCs, MediaFinder®-Standard Periodical Directory, MEDLINE/PubMed, PubsHub, Scilit, Scopus, Suweco CZ, TOC Premier and Ulrich's Periodicals Directory, and has successfully completed 13 years of scientific publications. Particularly it is motif of satisfaction that the CiteScoreTracker 2021 updated 5th of January is 2.6, anticipating an increase in comparison to 2020, which was 1.9.

During 2021 our life was still largely affected by the novel virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the COVID-19 disease. It was particularly amazing and a real motive of scientific pride that in just a few months we have had a new vaccine on the market. Specific treatments for COVID-19 were then developed, and the list of tested drugs does not stop to increase with some advances and setbacks.

My continuous experience in teaching students with different backgrounds, both from the pre- and post-graduation courses, offers me, as a teacher and researcher, a wide view regarding their training needs. These requirements should be always based on scientific evidence and on the expectations of the different professional groups that interact with each other, such as Physicians, Pharmacists, Forensic Specialists, Biomedical Specialists, Diagnostic and Therapeutic Technicians, Dentists, Law, among others. It is in this binomial that Nature advocates that it will be possible to build the scientist of the 21st century [1], and this is a perspective with which I fully agree. Therefore, in 2022, we aim to publish new scientific advances on pedagogical innovation in the area of pharmacology and toxicology. We will also be particularly interested in receiving submissions in the field of drug discovery and in the development of new treatments for COVID-19, namely those focusing on their biological targets and biomarkers, mechanisms of action, pharmacokinetics and pharmacodynamics, analytical techniques for diagnosis, preclinical experimentation, and clinical trials. Drug delivery, dermal and transdermal formulations to reduce toxicity of hepatic first passage routes, nanomedicines, drug targeting and research on plant-derived pharmaceuticals as a potential source of new treatments or that may work as an adjuvant for conventional treatments, are also topics welcome topics.

CDRR will continue to be a platform for more detailed discussions in the topics of pharmacokinetics, pharmacodynamics, and analytics aspects of all drugs. The mechanisms of carcinogenicity of marketed drugs, candidates or mixtures are also a issue that will deserve CDRR attention. The development and validation of analytical methods for the identification and quantification of new psychoactive substances in classical and alternative matrices is also an aspect that needs to be developed. An interesting field for research would be also psychopharmacology and the emergence of new treatments for psychiatric disorders specially if refractory to conventional treatments and how these pathologies can be influenced by genetic polymorphisms.

My last words go-to authors and reviewers, outstanding talented experts that have generously contributed with their knowledge to CDRR improvement, and to the in-house team, particularly Syeda Mehak Fatima, Assistant Publication Manager, who coordinated all the administrative submission steps, including typesetting and proof corrections.

REFERENCE


Ricardo Jorge Dinis-Oliveira
(Editor-in-Chief)
TOXRUN – Toxicology Research Unit
University Institute of Health Sciences – CESPU, Crl.,
Faculty of Medicine and UCIBIO-REQUIMTE - University of Porto.
Central de Gandra Street, 1317
4585-116 Gandra, PRD
Portugal
E-mail: ricardo.dinis@iucs.cespu.pt; ricardinis@med.up.pt

2589-9783/22 © 2022 Bentham Science Publishers